AGM/EGMJun 9, 2026, 04:07 PM
Ligand Pharmaceuticals Stockholders Approve Amended 2002 Stock Plan
AI Summary
Ligand Pharmaceuticals held its 2026 Annual Meeting of Stockholders on June 5, 2026. During the meeting, stockholders approved an amendment and restatement of the Company's 2002 Stock Incentive Plan. Additionally, eight directors were elected to the Board, the selection of Ernst & Young LLP as the independent auditor was ratified, and a non-binding advisory resolution on executive compensation was approved.
Key Highlights
- Stockholders approved an amendment and restatement of the Company's 2002 Stock Incentive Plan with 16,643,281 votes for.
- Eight members were elected to the Board of Directors for terms expiring at the 2027 annual meeting.
- The selection of Ernst & Young LLP as the independent registered public accounting firm for 2026 was ratified with 18,526,515 votes for.
- A non-binding advisory resolution regarding named executive officer compensation was approved with 16,497,712 votes for.
Price Impact
More from LGND